Italia Markets close in 3 hrs 4 mins

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
7,16-0,04 (-0,56%)
Alla chiusura: 04:00PM EDT
7,16 0,00 (0,00%)
Dopo ore: 04:03PM EDT

Bioventus Inc.

4721 Emperor Boulevard
Suite 100
Durham, NC 27703
United States
919 474 6700
https://www.bioventus.com

Settore/iHealthcare
SettoreMedical Devices
Impiegati a tempo pieno995

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Mark L. SingletonSenior VP & CFO740,04kN/D1970
Mr. Anthony D'AdamioSenior VP, General Counsel & Corporate Secretary705,38kN/D1961
Mr. Robert E. ClaypoolePresident, CEO & DirectorN/DN/D1972
Mr. Mike Crowe B.S., M.B.A.Senior Vice President of OperationsN/DN/DN/D
Mr. David CrawfordVice President of Investor Relations & TreasurerN/DN/DN/D
Ms. Katrina J. Church J.D.Senior VP & Chief Compliance OfficerN/DN/D1962
Ms. Helen LeupoldSenior VP & Chief Human Resources OfficerN/DN/DN/D
Mr. Larry ChenManaging Director of China & Asia PacificN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di Bioventus Inc. al 1 luglio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 6; diritti degli azionisti: 5; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.